ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Is a Good Night's Sleep at the Top of Your Wishlist?

Ashwagandha Helps Hormones - Aids Arthritis

Why You Should Be Eating More Porcini Mushrooms

A Breathalyzer for Disease?

How Bacopa Can Help Improve Your Cognitive Function

Magnesium Reduces Diabetes and Helps Keep You Young

Lavender Aromatherapy Can Ease Pre-Op Anxiety

Give Your Health a Much-Needed Boost With Geranium

The Role of Resveratrol in Achieving Optimal Health

Could Coconut Oil Help Reduce Antibiotics?

 
Print Page
Email Article

Improved Awareness of Fibromyalgia by Both Physicians and Patients Will Drive the Drug Market, According to a New Study from Decision Resources

  [ 348 votes ]   [ Discuss This Article ]
www.ProHealth.com • June 21, 2005


Tuesday June 21, 8:00 am ET Although the Fibromyalgia Market Will More Than Triple in Size Over the Next Decade, it Will Remain Small in Comparison with Primary Target Markets Such As Depression, Neuropathic Pain, and Insomnia WALTHAM, Mass., June 21 /PRNewswire/ -- Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that improved awareness of fibromyalgia among both physicians and patients will be a major market driver over the next ten years. Currently, less than 20% of fibromyalgia sufferers receive an accurate diagnosis. "Reasons for low diagnosis of fibromyalgia include an absence of official diagnostic and treatment guidelines, a paucity of effective therapies, and continuing reticence on the part of many physicians to recognize fibromyalgia as a true syndrome in its own right," said Tricia Nagle, analyst at Decision Resources, Inc. "We expect notable improvements in diagnosis over the next ten years as a result of the publication of official treatment (and possibly diagnostic) guidelines and the approval of several new drug therapies to treat the condition. New drug approvals will not only help to validate fibromyalgia syndrome in the minds of physicians, but will also bring about a new era of drug marketing." The new Pharmacor study entitled Fibromyalgia also finds that, although the fibromyalgia market has clear potential, it remains a secondary target for most drug companies. Primary markets such as depression, neuropathic pain, or insomnia represent much more lucrative target markets than fibromyalgia, so many companies will investigate their drugs for fibromyalgia only after they have secured a place in one of the more lucrative markets. About Fibromyalgia Fibromyalgia is one of the most common diagnoses made in rheumatological practice, yet the causes of this condition remain unknown and the treatments remain largely ineffective. Indeed, no drugs are yet labeled to treat fibromyalgia in any of the major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). About Pharmacor from Decision Resources Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development. About Decision Resources Decision Resources, Inc., (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders. For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 emarshall@dresources.com



Post a Comment

Featured Products From the ProHealth Store
Optimized Curcumin Longvida® Ultra EPA  - Fish Oil FibroSleep™


Article Comments



Be the first to comment on this article!

Post a Comment


 
Optimized Curcumin Longvida with Omega-3

Featured Products

Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function

Natural Remedies

Probiotic Mint Promotes Healthy Gums & Teeth, Freshens Breath and Whitens Teeth Probiotic Mint Promotes Healthy Gums & Teeth, Freshens Breath and Whitens Teeth
More Weight Loss than Any Other Discovery in Supplement History More Weight Loss than Any Other Discovery in Supplement History
A Hard-Working Molecule that May Help Ease Pain & Brighten Mood A Hard-Working Molecule that May Help Ease Pain & Brighten Mood
The Revolutionary 'Good Fat' That Promotes Heart, Brain, Bone and Joint Health The Revolutionary 'Good Fat' That Promotes Heart, Brain, Bone and Joint Health
Joint Aches May Have Met Their Match in Curcumin Joint Aches May Have Met Their Match in Curcumin

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map